Follow
Brigitta Derendinger
Brigitta Derendinger
Verified email at sun.ac.za
Title
Cited by
Cited by
Year
Bedaquiline microheteroresistance after cessation of tuberculosis treatment
M De Vos, SD Ley, KB Wiggins, B Derendinger, A Dippenaar, ...
New England Journal of Medicine 380 (22), 2178-2180, 2019
582019
An all-oral 6-month regimen for multidrug-resistant tuberculosis: a multicenter, randomized controlled clinical trial (the NExT study)
A Esmail, S Oelofse, C Lombard, R Perumal, L Mbuthini, ...
American Journal of Respiratory and Critical Care Medicine 205 (10), 1214-1227, 2022
562022
Diagnostic accuracy and utility of FluoroType MTBDR, a new molecular assay for multidrug-resistant tuberculosis
M de Vos, B Derendinger, T Dolby, J Simpson, PD van Helden, JE Rice, ...
Journal of clinical microbiology 56 (9), 10.1128/jcm. 00531-18, 2018
432018
Comparative diffusion of drugs through bronchial tissue
JM van Zyl, B Derendinger, HI Seifart, P Van der Bijl
International journal of pharmaceutics 357 (1-2), 32-36, 2008
182008
Mycobacterial genomic DNA from used Xpert MTB/RIF cartridges can be utilised for accurate second-line genotypic drug susceptibility testing and spoligotyping
R Venter, B Derendinger, M De Vos, S Pillay, T Dolby, J Simpson, ...
Scientific reports 7 (1), 14854, 2017
142017
Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment
SB Georghiou, TC Rodwell, A Korobitsyn, SH Abbadi, K Ajbani, ...
European Respiratory Journal 59 (4), 2022
102022
Widespread use of incorrect PCR ramp rate negatively impacts multidrug-resistant tuberculosis diagnosis (MTBDRplus)
B Derendinger, M De Vos, RR Nathavitharana, T Dolby, JA Simpson, ...
Scientific reports 8 (1), 3206, 2018
102018
Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study
B Derendinger, A Dippenaar, M de Vos, S Huo, R Alberts, R Tadokera, ...
The Lancet Microbe 4 (12), e972-e982, 2023
92023
Diagnostic accuracy of the FluoroType MTB and MTBDR VER 2.0 assays for the centralized high-throughput detection of Mycobacterium tuberculosis complex DNA and isoniazid and …
A Dippenaar, B Derendinger, T Dolby, N Beylis, PD van Helden, G Theron, ...
Clinical Microbiology and Infection 27 (9), 1351. e1-1351. e4, 2021
82021
Extract from used Xpert MTB/RIF Ultra cartridges is useful for accurate second-line drug-resistant tuberculosis diagnosis with minimal rpoB-amplicon cross …
R Venter, S Minnies, B Derendinger, H Tshivhula, M De Vos, T Dolby, ...
Scientific Reports 10 (1), 2633, 2020
62020
Detection of second line drug resistance among drug resistant Mycobacterium tuberculosis isolates in Botswana
T Mogashoa, P Melamu, B Derendinger, SD Ley, EM Streicher, T Iketleng, ...
Pathogens 8 (4), 208, 2019
62019
Continuous cough monitoring: a novel digital biomarker for TB diagnosis and treatment response monitoring
S Huddart, L Asege, D Jaganath, M Golla, H Dang, L Lovelina, ...
The International Journal of Tuberculosis and Lung Disease 27 (3), 221-222, 2023
52023
High frequency of bedaquiline resistance in programmatically treated drug-resistant TB patients with sustained culture-positivity in Cape Town, South Africa
B Derendinger, A Dippenaar, M de Vos, S Huo, R Alberts, R Tadokera, ...
medRxiv, 2022.11. 14.22282167, 2022
52022
Non-actionable Results, Accuracy, and Effect of First-and Second-line Line Probe Assays for Diagnosing Drug-Resistant Tuberculosis, Including on Smear-Negative Specimens, in a …
S Pillay, M de Vos, B Derendinger, EM Streicher, T Dolby, LA Scott, ...
Clinical Infectious Diseases 76 (3), e920-e929, 2023
32023
Frequent suboptimal thermocycler ramp rate usage negatively impacts GenoType MTBDRsl VER 2.0 performance for second-line drug-resistant tuberculosis diagnosis
B Derendinger, M de Vos, S Pillay, R Venter, J Metcalfe, Y Ghebrekristos, ...
The Journal of Molecular Diagnostics 24 (5), 494-502, 2022
32022
Evaluation of the Xpert MTB Host Response assay for the triage of patients with presumed pulmonary tuberculosis: a prospective diagnostic accuracy study in Viet Nam, India, the …
A Gupta-Wright, H Ha, S Abdulgadar, R Crowder, J Emmanuel, ...
The Lancet Global Health 12 (2), e226-e234, 2024
12024
Xpert MTB/RIF Ultra on contaminated liquid cultures for tuberculosis and rifampicin-resistance detection: a diagnostic accuracy evaluation
YT Ghebrekristos, N Beylis, CM Centner, R Venter, B Derendinger, ...
The Lancet Microbe 4 (10), e822-e829, 2023
12023
An all-oral 6-month regimen for multi-drug resistant/rifampicin-resistant tuberculosis: a multi-centre, phase 3, open label, randomised controlled trial (NeXT Study)
K Dheda, A Esmail, S Oelofse, C Lombard, R Perumal, L Mbuthini, ...
12021
Point-of-care C-reactive protein and Xpert MTB/RIF Ultra for tuberculosis screening and diagnosis in unselected antiretroviral therapy initiators: a prospective diagnostic …
BWP Reeve, G Ndlangalavu, H Mishra, Z Palmer, H Tshivhula, ...
medRxiv, 2023
2023
Appendix VI
SD Ley, B Derendinger
New and improved methods for the diagnosis of susceptibility to tuberculosis …, 2023
2023
The system can't perform the operation now. Try again later.
Articles 1–20